Keros Therapeutics, Inc.

Report azionario NasdaqGM:KROS

Capitalizzazione di mercato: US$222.1m

Keros Therapeutics Crescita futura

Criteri Future verificati 2/6

Si prevede che Keros Therapeutics aumenterà gli utili e i ricavi rispettivamente del 0.5% e 39.4% all'anno, mentre si prevede che l'EPS crescerà del 6.9% all'anno.

Informazioni chiave

0.5%

Tasso di crescita degli utili

6.90%

Tasso di crescita dell'EPS

Biotechs crescita degli utili25.4%
Tasso di crescita dei ricavi39.4%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento19 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Articolo di analisi • Nov 18

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Aug 21

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Summary Keros Therapeutics, Inc. faces uncertainty after discontinuing its lead asset, with current value driven mainly by a strong cash position and pipeline potential. KER-065 received FDA Orphan Drug designation for Duchenne Muscular Dystrophy, but efficacy and approval remain years away and unproven. Elritercept, now partnered with Takeda, offers milestone and royalty potential, but faces tough competition and uncertain commercial prospects. Given limited near-term catalysts and high risk, I maintain a Hold rating—Keros is interesting, but KROS stock lacks enough data for a bullish stance. Read the full article on Seeking Alpha
Articolo di analisi • May 29

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Key Insights Keros Therapeutics to hold its Annual General Meeting on 4th of June Salary of US$699.0k is part of CEO...
Articolo di analisi • May 14

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We did...
Articolo di analisi • May 09

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shares have had a really impressive month, gaining 44% after a shaky period...
Seeking Alpha • Mar 13

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Summary Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Despite a strong cash position and a Takeda partnership elsewhere, the future of Keros' lead candidate, Cibotercept, appears bleak. The company has a cash runway of 13 quarters, but high short interest and low trading volume pose additional risks. Given the current situation, I recommend avoiding KROS, although risk-loving investors might find its low price and cash reserves appealing. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Summary Keros Therapeutics, Inc.'s stock plummeted over 75% due to halting high-dose arms in its Phase 2 TROPOS trial for PAH, citing safety concerns. Despite the setback, Keros' partnership with Takeda Pharmaceutical Company for elritercept and its potential $900m annual revenue offers a safety net. The market reaction may be too harsh; past biotech clinical study setbacks have often been resolved, presenting a contrarian investment opportunity. Investors should wait for more data on cibotercept's safety issues before making definitive judgments. Read the full article on Seeking Alpha
Articolo di analisi • Nov 20

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Aug 07

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jun 10

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Summary Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with the FDA and agreed on a design for a phase 3 study using KER-050 for the treatment of low-risk MDS. The global myelodysplastic syndrome market is projected to reach $6.10 billion by 2029. Keros Therapeutics is also developing the use of KER-050 for the treatment of patients with myelofibrosis and data from the phase 2 study for this program is expected in Q4 2024. Read the full article on Seeking Alpha
Articolo di analisi • Apr 23

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Key Insights The projected fair value for Keros Therapeutics is US$94.52 based on 2 Stage Free Cash Flow to Equity...
Articolo di analisi • Sep 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Jun 10

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Articolo di analisi • Sep 08

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 04

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Keros Therapeutics press release (NASDAQ:KROS): Q2 GAAP EPS of -$1.13 misses by $0.07. Cash and cash equivalents OF $215.62M
Articolo di analisi • Apr 29

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jan 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • May 05

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:KROS - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202856-110-102N/A7
12/31/202712-142-107N/A7
12/31/20264-123-94N/A7
3/31/202633-85-58-57N/A
12/31/202524487106108N/A
9/30/2025247648789N/A
6/30/2025233195355N/A
3/31/202521544345N/A
12/31/20244-187-163-161N/A
9/30/20241-182-143-140N/A
6/30/20240-168-146-144N/A
3/31/20240-160-137-135N/A
12/31/20230-153-127-125N/A
9/30/20230-142-123-120N/A
6/30/2023N/A-127-113-111N/A
3/31/2023N/A-116-105-103N/A
12/31/2022N/A-105-71-70N/A
9/30/202220-82-69-68N/A
6/30/202220-79-59-58N/A
3/31/202220-67-54-53N/A
12/31/202120-59-63-62N/A
9/30/20210-61-51-51N/A
6/30/20210-53-48-47N/A
3/31/2021N/A-49-40-39N/A
12/31/2020N/A-45-37-37N/A
9/30/20203-39-35-34N/A
6/30/20205-31-27-26N/A
3/31/20208-23-22-22N/A
12/31/201910-14N/A-16N/A
12/31/201810-2N/A7N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di KROS ( 39.4% all'anno) crescerà più rapidamente del mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di KROS ( 39.4% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di KROS è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/22 13:14
Prezzo dell'azione a fine giornata2026/05/21 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Keros Therapeutics, Inc. è coperta da 17 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jason ZemanskyBofA Global Research
Corinne JohnsonGoldman Sachs
Andrew FeinH.C. Wainwright & Co.